Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Equillium

Nasdaq:EQ
Snowflake Description

Excellent balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
EQ
Nasdaq
$46M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Equillium, Inc., a biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The last earnings update was 2 days ago. More info.


Add to Portfolio Compare Print
  • Equillium has significant price volatility in the past 3 months.
EQ Share Price and Events
7 Day Returns
-18.9%
NasdaqGM:EQ
6.3%
US Biotechs
12.6%
US Market
1 Year Returns
-67.3%
NasdaqGM:EQ
1.6%
US Biotechs
-9.1%
US Market
EQ Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Equillium (EQ) -18.9% -48.5% -35% -67.3% - -
US Biotechs 6.3% -7.9% -7.9% 1.6% 7.7% -8.8%
US Market 12.6% -16.7% -19.6% -9.1% 8.2% 21.5%
1 Year Return vs Industry and Market
  • EQ underperformed the Biotechs industry which returned 1.6% over the past year.
  • EQ underperformed the Market in United States of America which returned -9.1% over the past year.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

EQ Value

 Is Equillium undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Equillium. This is due to cash flow or dividend data being unavailable. The share price is $2.62.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Equillium's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Equillium's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:EQ PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.47
NasdaqGM:EQ Share Price ** NasdaqGM (2020-03-27) in USD $2.62
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.87x
United States of America Market PE Ratio Median Figure of 2,935 Publicly-Listed Companies 13.38x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Equillium.

NasdaqGM:EQ PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:EQ Share Price ÷ EPS (both in USD)

= 2.62 ÷ -1.47

-1.78x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Equillium is loss making, we can't compare its value to the US Biotechs industry average.
  • Equillium is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Equillium's expected growth come at a high price?
Raw Data
NasdaqGM:EQ PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.78x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
-10.1%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.99x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1.03x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Equillium, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Equillium's assets?
Raw Data
NasdaqGM:EQ PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $2.40
NasdaqGM:EQ Share Price * NasdaqGM (2020-03-27) in USD $2.62
United States of America Biotechs Industry PB Ratio Median Figure of 428 Publicly-Listed Biotechs Companies 2.47x
United States of America Market PB Ratio Median Figure of 5,145 Publicly-Listed Companies 1.27x
NasdaqGM:EQ PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:EQ Share Price ÷ Book Value per Share (both in USD)

= 2.62 ÷ 2.40

1.09x

* Primary Listing of Equillium.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Equillium is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Equillium's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Equillium has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

EQ Future Performance

 How is Equillium expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-10.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Equillium expected to grow at an attractive rate?
  • Unable to compare Equillium's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Equillium's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Equillium's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:EQ Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:EQ Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts -10.1%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.7%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:EQ Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:EQ Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 76 -17 -26 2
2023-12-31 40 -46 -55 2
2022-12-31 11 -52 -62 1
2021-12-31 0 -27 -37 1
2020-12-31 0 -22 -30 2
2020-03-28
NasdaqGM:EQ Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -23 -26
2019-09-30 -18 -23
2019-06-30 -15 -22
2019-03-31 -11 -18
2018-12-31 -8 -13
2018-09-30 -4 -10
2017-12-31 -1 -3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Equillium is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Equillium is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:EQ Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Equillium Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:EQ Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 0.08 1.03 -0.88 2.00
2023-12-31 -0.99 -0.07 -1.91 2.00
2022-12-31 -1.90 -1.19 -2.61 2.00
2021-12-31 -1.40 -1.19 -1.61 2.00
2020-12-31 -1.43 -1.17 -1.68 2.00
2020-03-28
NasdaqGM:EQ Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.47
2019-09-30 -1.35
2019-06-30 -1.41
2019-03-31 -1.27
2018-12-31 -1.09
2018-09-30 -0.76
2017-12-31 -0.27

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Equillium will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Equillium's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Equillium has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

EQ Past Performance

  How has Equillium performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Equillium's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Equillium does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Equillium's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Equillium's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Equillium's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Equillium Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:EQ Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -25.60 9.09 17.64
2019-09-30 -23.02 8.63 14.71
2019-06-30 -21.93 7.49 11.75
2019-03-31 -17.62 5.89 8.04
2018-12-31 -13.25 3.67 4.94
2018-09-30 -9.82 2.20 3.17
2017-12-31 -2.71 0.45 1.60

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Equillium has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Equillium has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Equillium improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Equillium's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Equillium has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

EQ Health

 How is Equillium's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Equillium's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Equillium is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Equillium's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Equillium's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 5.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Equillium Company Filings, last reported 2 months ago.

NasdaqGM:EQ Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 41.85 9.68 53.14
2019-09-30 48.96 9.62 62.24
2019-06-30 54.06 0.00 56.94
2019-03-31 59.49 0.00 61.61
2018-12-31 64.94 0.00 65.91
2018-09-30 -10.38 11.60 4.98
2017-12-31 -2.25 8.06 7.10
  • Equillium's level of debt (23.1%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Equillium's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Equillium has sufficient cash runway for 2.3 years based on current free cash flow.
  • Equillium has sufficient cash runway for 1.6 years if free cash flow continues to grow at historical rates of 99.3% each year.
X
Financial health checks
We assess Equillium's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Equillium has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

EQ Dividends

 What is Equillium's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Equillium dividends.
If you bought $2,000 of Equillium shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Equillium's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Equillium's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:EQ Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1956 Stocks 2.9%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.9%
United States of America Top 25% Dividend Yield 75th Percentile 5.3%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:EQ Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-03-28

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Equillium has not reported any payouts.
  • Unable to verify if Equillium's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Equillium's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Equillium has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Equillium's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Equillium afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Equillium has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

EQ Management

 What is the CEO of Equillium's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Bruce Steel
COMPENSATION $0
AGE 53
TENURE AS CEO 0.2 years
CEO Bio

Mr. Bruce D. Steel, CFA has been Chief Executive Officer of Equillium, Inc. since January 1, 2020. He has been a Managing Director at BioMed Ventures LP since September 2010. Mr. Steel serves as President since June 2018 & Director since March 2017 at Equillium, Inc. He is co-founder of Equillium, Inc and was its Chief Business Officer until January 1, 2020. Mr. Steel serves as an officer on the executive team of BioMed Realty Trust Inc. Since 2005 until its acquisition in 2008, he was Co-Founder of Rincon Pharmaceuticals, Inc., and served as its Chief Executive Officer from 2005 until its acquisition in 2008. Mr. Steel served as Chief Business Officer of RuiYi Inc. He served as the Head of Corporate Development at Ambit Biosciences from 2002 to 2005. Prior to Ambit, Mr. Steel directed corporate development at Akesis Pharmaceuticals, a diabetes therapy company founded by Kevin Kinsella (Avalon Ventures). He served as Chairman of Board of Directors of Zosano Pharma Corporation from 2012 to 2017. From 2008 to 2010, Mr. Steel served as the Chief Business Officer at Anaphore, Inc., a privately-held pharmaceutical company. Mr. Steel served as a Director at AEGEA Medical Inc., until 2020. He serves as Director of Breathe Technologies, Inc. Mr. Steel is the founder of BioMed Ventures, an investment firm owned by BioMed Realty, LP, since 2010. He served as Chairman of Board of Directors of Rincon Pharmaceuticals Inc. Mr. Steel served as a Board Observer at TRACON Pharmaceuticals, Inc. since September 22, 2014. He served as a Director of Zosano, Inc. from October 31, 2013 to April 7, 2014. He received his Bachelor of Arts degree from Dartmouth College in 1988, his Masters of Business Administration Degree from the Marshall School of Business at the University of Southern California in 1995 and holds the designation of Chartered Financial Analyst.

CEO Compensation
  • Insufficient data for Bruce to compare compensation growth.
  • Insufficient data for Bruce to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Equillium management team in years:

1.6
Average Tenure
48.5
Average Age
  • The average tenure for the Equillium management team is less than 2 years, this suggests a new team.
Management Team

Dan Bradbury

TITLE
Executive Chairman
COMPENSATION
$315K
AGE
58
TENURE
0.2 yrs

Stephen Connelly

TITLE
Chief Scientific Officer & Director
COMPENSATION
$374K
AGE
37
TENURE
2.2 yrs

Krishna Polu

TITLE
Executive Vice President Research & Development
COMPENSATION
$3M
AGE
46
TENURE
1.6 yrs

Bruce Steel

TITLE
Co-Founder
AGE
53
TENURE
0.2 yrs

Jason Keyes

TITLE
Chief Financial Officer
AGE
48
TENURE
2 yrs

Christine Zedelmayer

TITLE
Senior VP & COO
AGE
49

Joel Rothman

TITLE
Senior Vice President of Development Operations
Board of Directors Tenure

Average tenure and age of the Equillium board of directors in years:

2.8
Average Tenure
58
Average Age
  • The average tenure for the Equillium board of directors is less than 3 years, this suggests a new board.
Board of Directors

Dan Bradbury

TITLE
Executive Chairman
COMPENSATION
$315K
AGE
58
TENURE
3 yrs

Stephen Connelly

TITLE
Chief Scientific Officer & Director
COMPENSATION
$374K
AGE
37
TENURE
3 yrs

Bruce Steel

TITLE
Co-Founder
AGE
53
TENURE
3 yrs

Martha Demski

TITLE
Independent Director
COMPENSATION
$255K
AGE
66
TENURE
1.5 yrs

Bala Manian

TITLE
Independent Director
COMPENSATION
$14K
AGE
74
TENURE
2.8 yrs

Charlie McDermott

TITLE
Independent Director
COMPENSATION
$254K
AGE
47
TENURE
1.5 yrs

Mark Pruzanski

TITLE
Independent Director
COMPENSATION
$252K
AGE
51
TENURE
1.5 yrs

Vijay Kuchroo

TITLE
Member of Scientific & Clinical Advisory Board
AGE
64

Fred Ramsdell

TITLE
Member of Scientific & Clinical Advisory Board
AGE
58

Pradip Nair

TITLE
Member of Scientific & Clinical Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Equillium's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Equillium has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

EQ News

Simply Wall St News

How Much Of Equillium, Inc. (NASDAQ:EQ) Do Insiders Own?

Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. … I quite like to see at least a little bit of insider ownership. … We can zoom in on the different ownership groups, to learn more about EQ

Simply Wall St -

EQ Company Info

Description

Equillium, Inc., a biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is EQ001, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was founded in 2017 and is headquartered in San Diego, California.

Details
Name: Equillium, Inc.
EQ
Exchange: NasdaqGM
Founded: 2017
$45,525,738
17,376,236
Website: http://www.equilliumbio.com
Address: Equillium, Inc.
2223 Avenida De La Playa,
Suite 105,
San Diego,
California, 92037,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM EQ Common Stock Nasdaq Global Market US USD 12. Oct 2018
DB 0FY Common Stock Deutsche Boerse AG DE EUR 12. Oct 2018
Number of employees
Current staff
Staff numbers
16
Equillium employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 02:51
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/27
Last earnings filing: 2020/03/26
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.